| Date | Title | Description | |
|---|---|---|---|
| 07 Nov 2024 | On P&L | The Company releases the first nine months 2024 financial results presentation | Download |
| 24 Oct 2024 | On corporate transactions | ROVI completes the strategic review of its CDMO business | Download |
| 31 Jul 2024 | On P&L | The Company releases the press release related to the first half 2024 financial results | Download |
| 31 Jul 2024 | On P&L | The Company releases the first half 2024 financial results presentation | Download |
| 26 Jun 2024 | On corporate transactions | ROVI notes the recent press speculation and informs about the assessment of potential strategic alternatives | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 03 Nov 2021 | On business and financial situation | The Company releases the press release related to the first nine months 2021 financial results | Download |
| 21 Oct 2021 | Liquidity and counterparty agreements | Download | |
| 21 Oct 2021 | On business and financial situation | The Company informs of the delay in the decision on Risperidone ISM® by the U.S. Food and Drug Administration (“FDA”). | Download |
| 07 Oct 2021 | Liquidity and counterparty agreements | Download | |
| 04 Oct 2021 | Liquidity and counterparty agreements | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 09 Oct 2015 | Otros sobre operaciones corporativas | Download | |
| 08 Oct 2015 | Otros sobre operaciones corporativas | Download | |
| 30 Jul 2015 | Información sobre resultados (2) | Download | |
| 30 Jul 2015 | Información sobre resultados | Download | |
| 30 Jun 2015 | Información sobre dividendos | Download |